Patents by Inventor Jialu Mo

Jialu Mo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO CD70, AND APPLICATION THEREOF
    Publication number: 20230399412
    Abstract: A CD70 antibody and a chimeric antigen receptor (CAR) that can specifically bind to a CD70 protein. The CAR comprises a CD70 binding domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain. Further disclosed is an application of the antibody and the CAR for treating diseases or conditions related to CD70 expression.
    Type: Application
    Filed: October 12, 2021
    Publication date: December 14, 2023
    Applicant: Nanjing IASO Biotechnology Co., Ltd.
    Inventors: Yongkun Yang, Guang Hu, Panpan Niu, Guangrong Meng, Jialu Mo, Jianhua Zhang, Qianli Hu, Wei Cheng, Taochao Tan, Qiaoe Wei, Xiangyin Jia, Zhenyu Dai
  • FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD22 AND USE THEREOF
    Publication number: 20230241212
    Abstract: Provided is a bispecific chimeric antigen receptor targeting CD19 and CD22, which comprises extracellular antigen binding domains of heavy-chain variable regions and light-chain variable regions of anti-CD19 and anti-CD22 antibodies. Further provided is a bispecific CAR-T cell targeting CD19 and CD22.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 3, 2023
    Applicant: Nanjing IASO Biotherapeutics Co., Ltd.
    Inventors: Yongkun Yang, Guang Hu, Taochao Tan, Zhenyu Dai, Panpan Niu, Guangrong Meng, Wei Cheng, Xiangyin Jia, Jialu Mo, Wen Wang, Bailu Xie, Junfeng Yang, Fei Zhou
  • FULLY HUMAN ANTI-HUMAN CD22 CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF
    Publication number: 20230174654
    Abstract: The present invention provides an anti-CD22 antibody molecule and a CD22-targeted chimeric antigen receptor (CAR) constructed using the anti-CD22 antibody molecule. The present invention also provides an application of the anti-CD22 antibody molecule and the CAR in the preparation of drugs for treating CD22-related diseases.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 8, 2023
    Applicant: Nanjing IASO Biotherapeutics Co., Ltd.
    Inventors: Guang Hu, Yongkun Yang, Panpan Niu, Guangrong Meng, Wei Cheng, Jialu Mo